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Abstract 
Spontaneous coronary artery dissections (SCADs) are increasingly recognized as an important cause 
of acute coronary syndromes in predominantly  women below 60 years of age. SCAD patients 
comprise a heterogeneous group, in which it is estimated that a quarter to one third have underlying 
fibromuscular dysplasia (FMD). Although the mutual relationship of SCAD and FMD is complex and 
only partly understood, there seems to be some overlap in genetic background and interaction with 
endogenous sex-steroids. In this review we provide an update of our current knowledge on these 
intriguing emerging arteriopathies.  
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Introduction 
An acute coronary syndrome (ACS) caused by a spontaneous coronary artery dissection 
(SCAD) is less rare than previously considered and occurs 9 times more often in women than in 
men[1]. A SCAD is defined as an acute development of a false lumen within the arterial wall, either 
caused by an intimal tear or an acute bleeding within the tunica media of the coronary artery wall.  
This leads to a compression of the true lumen, resulting in the clinical features of an ACS. In most 
cases women between 35-65 years are affected, with a peak around 53 years of age [2-4]. It is 
estimated that up to 25% of all ACS within this age-group are caused by SCAD. Fewer than 10% of all 
SCADs appear in (late) pregnancy or after delivery (P-SCAD). In clinical practice, a SCAD is diagnosed 
by acute chest pain, (N)STEMI changes on the ECG, elevation of Troponins and characteristics at 
coronary angiography.   The number of SCADs is still underestimated, as the angiographic features 
may be mistakenly for atherosclerosis [5]. Three major types of angiographic characteristics can be 
identified: type I with a double lumen, type II with a long and smooth stenosis and type III with an 
atherogeneous-like aspect. In addition, increased coronary tortuosity is often present.  In case of 
uncertainty intracoronary imaging with OCT/IVUS can be done to establish the correct diagnosis. In 
almost 60% of cases the LAD is affected, followed by the RCA (26%) and RCX (19%)[6].  Although 
hypertension is present in one third of SCAD patients, other traditional cardiovascular disease (CVD) 
risk factors are less often reported than in traditional ACS [1]. Predisposing factors for the 
heterogeneous population of SCAD patients are female sex, pregnancy-related factors and hereditary 
mixed connective tissue disorders, whereas there are possibly associations with hormonal therapy, 
fibromuscular dysplasia (FMD) and inflammatory disorders.   Emotional or physical triggers may act 
as precipitating stressors [3]. Gender differences in the pathophysiological impact of stress may be 
one of the reasons why an ACS caused by SCAD is so disproportionately predominant in women [3, 7, 
8]. Fibromuscular dysplasia is the most commonly observed arteriopathy associated with SCAD. 
Patient series report a wide range in prevalence of FMD, varying between 17-86% [9]. As many SCAD 
patients are not routinely examined for FMD, more precise estimates are lacking. Like SCAD, FMD 
also has a strong female predominance (>80%) and it affects the renal and carotid arteries in about 
75% of patients [10, 11]. Fibromuscular dysplasia can manifest as vascular stenosis, aneurysm, 
dissection, occlusion or arterial tortuosity. Preliminary data from the US registry suggest that women 
may have more frequently carotid FMD lesions than men (74.9 vs. 44.1%, p=0.0004). On the 
contrary, renal FMD might be even more frequent in men than in women (89.7 vs. 74.1%, p=0.032) 
[12]. Up to now the strong female predominance in SCAD and FMD patients suggest that sex- and 
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gender related factors are important in both entities and possibly also in their mutual relationship. In 
this paper we aim to focus on common aspects of SCAD and FMD.  
 
Role of sex steroids and TGF-beta in arterial malformations  
Both estrogens and androgens are involved in the development of CVD and hypertension. Estrogens 
have complex but important regulating effects on vascular reactivity, blood pressure, endothelial 
relaxation and cardiac/vascular remodeling through genomic and non-genomic effects [13-15]. Rapid 
actions of estrogens include the ability to stimulate endothelial NO synthase (eNOS) in vascular 
endothelial cells and the inhibition of proliferation of smooth muscle cells (SMC). Estrogens also 
modulate angiogenic factors, such as matrix metallo-proteinases (MMPs) and tissue growth factor-β 
(TGF-β). Elevated levels of TGF-β have been found in patients with the Marfan syndrome and in 
patients with FMD [16, 17]. Estrogen decreases deposition of collagen and increases deposition of 
elastin, whereas testosterone has an opposite effect [18]. This is mediated by the expression of 
important MMPs  including collagen, elastin, and fibrillin-1 and their regulators. In contrast, 
progesterone attenuates the increase in elastin deposition observed with 17 β-estradiol alone. A 
possibly consequence is that high cyclic progesterone levels in premenopausal women may 
attenuate the beneficial effects  of 17 β estradiol on the elastin/collagen ratio of the vascular wall. 
Cyclic symptoms in women before/after SCAD have been reported [19].  After menopause low 17 β 
estradiol levels enhance vascular stiffness and lower arterial compliance, resulting in more stiffened 
arteries and higher pulse pressure in elderly women than in age-matched males [20, 21].  Modulation 
of sex steroid levels  with ageing are therefore likely to interact with important sex differences in 
arterial stiffness across the lifespan. While a small study performed in a limited number of samples 
suggests  that progesterone receptors are expressed in the nuclei of vascular smooth muscle cells of 
renal arteries from patients with FMD (n=6)  but not from controls (n=3) [22] , the role of sex 
hormones including progesterone in the pathophysiology of arterial changes in FMD needs to be 
further explored.  
TGF-β enhances the production of collagen and the remodeling of the extracellular matrix 
[23]. Overproduction of TGF-β in Marfan patients reduces connective tissue elasticity and leads to 
weakness of the vascular wall. Aortic manifestations of the disease occur predominantly in male 
patients [24].  Arterial tortuosity in the coronary arteries is often present in SCAD patients (figure 1) 
and is a major though insufficiently  studied vascular phenotype of FMD [25]. Increased TGF-β activity 
has been postulated to affect the degree of arterial tortuosity[26] . Accordingly, genetic syndromes in 
which arterial tortuosity is at the forefront, such as the Loeys Dietz syndrome and the rare 
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Aneurysms Osteoarthritis Syndrome,  are due to mutations in genes involved in the TGF- beta 
pathway (TGFBR1/TGFBR2 and SMAD3, respectively) [27, 28]. Hypertension is in part regulated by 
steroid sex hormones and probably plays an important role in the pathophysiology of arterial 
tortuosity[29].   
 
SCAD in pregnancy  
Although SCAD was once considered primarily a peripartum condition, it is now clear from large 
multinational registry studies that pregnancy-associated SCAD (P-SCAD) accounts for a minority 
(≤10%) of women with SCAD [2, 3, 7, 30-32]. However SCAD accounts for around a quarter of ACS 
occurring during pregnancy and half of ACS in post partum patients [33, 34]. Most P-SCAD events 
occur in a period from the third trimester of pregnancy peaking in the early (up to 6-months) post 
partum period but cases have been reported throughout gestation and late (up to 2-years) post 
partum, including in association with breast feeding (or the recent cessation of breast feeding) [35-
37]. At present it is unclear if these very early or very late events represent true P-SCAD or are due to 
sporadic SCAD recurrence occurring by coincidence at these times. The true at-risk period for P-SCAD 
therefore remains ill-defined. Despite a hypothetical mechanistic association with increased coronary 
sheer stress, delivery per se does not appear to be a prime driver of P-SCAD events [37]. The very 
high progesterone-levels during pregnancy and the rapid hormonal changes thereafter may be an 
important reason why SCADs occur more often during or shortly after pregnancy.   
Acute management of P-SCAD presents a unique series of challenges and requires a careful 
multidisciplinary approach with close monitoring of mother and fetus. [38] There is growing evidence 
that P-SCAD patients present with a more extreme SCAD phenotype characterized by more proximal 
coronary involvement and a higher proportion of ST-elevation myocardial infarction (STEMI), 
cardiogenic shock, arrhythmia (including as a cause of maternal death) and a reduction in post infarct 
ejection fraction [37, 39, 40]. The suggested approach to coronary management in P-SCAD is based 
on expert consensus. [35, 36, 38] The benefits of an accurate angiographic diagnosis and risk 
stratification outweigh the fetal X-ray exposure , which is manageable with contemporary 
techniques. [38] In line with general recommendations in patients with SCAD, a conservative 
approach to revascularization is favored, reserving percutaneous coronary intervention (PCI) for 
cases with poor or absent coronary flow, ongoing evidence of significant ischaemia or infarction and 
a large myocardial area in jeopardy. [35, 36, 38, 41] Coronary bypass surgery may be a useful bail-out 
in extremely high risk scenarios such as unstable proximal dissections or a failure of PCI to restore 
flow to a large myocardial territory but increased late graft failure following healing of the native 
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coronary circulation has been reported. [2] Timing and mode of delivery should be an individualized 
multi-disciplinary decision[41]. Time interval since SCAD, left ventricular function, use of antiplatelet 
therapy and presence of a known connective tissue disorders or aortopathy will impact on this 
decision. Operative delivery is not mandatory in all cases and consideration of supported vaginal 
delivery with measures to minimize cardiac demand has been advocated. [38] There is currently very 
limited data on the risk of pregnancy in survivors of SCAD. Recurrence is well recognized in SCAD and 
is a potential additional concern over and above the issues of teratogenicity, the impact of left 
ventricular impairment and the risk of stent thrombosis on pregnancy risk. [36, 38, 42] A single series 
of nine pregnancies in survivors of SCAD reported a single recurrent SCAD occurring 9 weeks post 
partum. [43] It is not currently clear to what extent pregnancy per se constitutes an additional risk 
over and above the background recurrence risk in SCAD. However, patients should avoid unplanned 
pregnancy and those contemplating planned pregnancy should be carefully counseled [41]. 
The risks of pregnancy in patients with FMD are less well studied. However, several elements 
should be kept in mind. First, patients with FMD may harbour aneurysms  of renal or visceral arteries, 
with a potentially increased risk of rupture during pregnancy [44, 45]. Second, a retrospective study 
by Vance et al. suggests a substantially increased risk of preeclampsia in women with FMD [46].  
Finally, in some instances, hypertension due to renal artery FMD may become refractory during 
pregnancy [47]. Accordingly, screening for renal artery FMD using sensitive methods such as CT- or 
MR-angiography is worth considering in all hypertensive women planning a pregnancy. In case of 
FMD lesions of renal arteries requiring revascularization, percutaneous angioplasty should be 
performed before pregnancy, and a comprehensive vascular screening (from brain to iliac arteries) 
should be foreseen, in order to rule out the existence of aneurysms or dissections of other arterial 
beds. Finally, patients with known FMD who decide to become pregnant should be followed in a high 
volume obstetrical centre with expertise in at-risk pregnancies [41], in tight collaboration with a 
specialist in vascular medicine or FMD expert. 
Risk factors and precipitators  for SCAD   
A large number of conditions have been described in case reports or small case series in patients 
with SCAD. [35, 36] However, many of these are probably simply co-incident conditions rather than 
true risk factors. It is now well-recognized that SCAD is not confined to women of child-bearing 
potential but that its incidence extends well into the post-menopausal years. [35, 36] Furthermore, 
although exogenous sex hormones (i.e. hormonal contraception and hormone replacement therapy) 
are frequently considered a risk, [3, 30, 48-50] given the highly prevalent population use of these 
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drugs, an association with either SCAD or SCAD recurrence has yet to be clearly established and the 
relative risk or benefit of specific hormone treatment strategies is unknown. 
The precise relationship between exercise and SCAD is also complex. It is clear that extreme (and 
particularly isometric) exercise can rarely trigger SCAD, [51-55] with an association reportedly more 
frequent in men. [8] There also seem to be a subset of SCAD patients who exercise to a high (if not 
elite) level. In these patients the temporal association between specific exercise episodes and the 
onset of SCAD-related symptoms does not suggest that exercise is acting as a trigger. [42] There is no 
evidence that exercise is a precipitating factor for SCAD recurrence and whilst avoidance of extreme 
exercise seems sensible, cardiac rehabilitation is reportedly beneficial. [56, 57] 
It is increasingly recognized that SCAD is one of a series of partially overlapping disorders. These 
include hereditary connective tissue disorders (CTD), FMD, cervical and intracerebral dissection, 
migraine and pre-eclampsia (Figure 2). [35, 36] These associations maybe partly genetic (see below) 
but the precise mechanisms explaining the interrelationship between these conditions remain to be 
elucidated.  In some series the occurrence of SCAD has been associated with (systemic)  
inflammatory disorders and autoimmune diseases, but this has not been reported by others [3, 4]. 
Thus far, inflammation has not been found to be associated with FMD[10]. 
Psychosocial stress-related factors and SCAD   
Severe emotional distress is a potential trigger for an ACS in both women and men, but coping with 
stress is importantly different among both genders [3, 58, 59]. Psychosocial stress is often reported 
by SCAD patients in the months/weeks before the acute event.  This may act as a ‘trigger’ for SCAD.  
One working hypothesis in SCAD patients is that (prolonged) emotional distress leads to endothelial 
dysfunction and low-thresholds for vascular spasm. These pathophysiological processes may create a 
substrate that increases the vulnerability for a sudden intimal tear in the vessel wall that is triggered 
by physical and emotional stressors, resulting in a SCAD. As a SCAD usually occurs in previously 
‘healthy’ young women, the impact of such an event is huge. The use of antidepressants/anxiolytic 
agents has been reported in more than 30% of patients after SCAD [60]. Mental stress-induced 
ischemia occurs twice as often in women after ACS than in men [61]. This may account for the 
relative high percentage (>50%) of reported residual symptoms in predominant women after SCAD  
[62]. Patients with FMD also report an array of psychological symptoms and concerns [63]. Whether 
the latter are secondary to the announcement of the disease, severity of complications and related 
anxiety or, at least in some patients, may  be part of  the disease spectrum is the object of current 
investigations. 
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Genetic aspects of SCAD and FMD  
There is evidence for a genetic component for SCAD and FMD but the identification of the genetic 
causes has been a challenging task. Familial recurrence was investigated in a series of ~100 FMD 
patients and their hypertensive relatives and concluded to the presence of familial FMD in ~11% of 
cases, with no evidence for a more severe presentation among familial versus sporadic cases [64]. 
However, such familial cases may be overrepresented in a highly specialized FMD center. By contrast, 
in registries, familial FMD was reported in only 2.8-2.9% of symptomatic cases, though admittedly 
systematic screening of asymptomatic family members may have led to a higher prevalence[65, 66]. 
Familial cases of SCAD were reported to be rare (<2%) in series of over 400 patients and were limited 
to siblings or mother-daughter pairs [67]. SCAD and FMD were considered for long time rare vascular 
diseases and their clinical overlap with some rare CTD suggested that a similar genetic model might 
apply to their mode of inheritance. Features of CTD appear to be more frequent  in patients with 
FMD, though data on the prevalence of such systemic manifestations are conflicting [17].  Notably 
however, such patients generally do not harbour mutations in genes causative for vascular and 
connective tissue Mendelian disorders (e.g Marfan, Loeyz-Dietz, vascular Ehlers Danlos syndromes 
among others) [16]. This finding further supports a previous investigation that showed low yield of 
genetic testing in patients with FMD for most of known vascular and connective tissue genes [68]. 
More recently, among 44 SCAD patients who underwent cardiovascular genetics testing in a 
prospective setting, 6 patients (~8%) had an identifiable genetic cause, with 3 patients carrying 
mutation in COL3A1, the causative gene for vEDS [69].  Overall, SCAD and FMD patients only 
exceptionally carry mutations for known genes of inherited vascular diseases and CTD. This motivates 
and encourages specific genetic investigation to understand the etiology of FMD and SCAD.  The 
investigation of the exomes of 16 FMD related patients showed genetic heterogeneity and made 
unlikely the existence of a major gene for FMD, although this study was underpowered and large-
scale exome studies are still missing[70]. A recent study identified the genetic cause of the Grange 
Syndrome, a rare autosomal-recessive disorder characterized by severe and early onset vascular 
abnormalities, comparable to focal FMD[71]. In this study, the author reported mutations in YY1P1 
encoding a protein involved in transcription regulation, DNA repair and replication and provided 
evidence for this gene to be important for the proliferation and TGF-beta mediated differentiation of 
vascular smooth muscle cells[71]. Given the rarity of this syndrome, only 1 frameshift mutation was 
found in YY1P1 in non syndromic FMD and this gene is thus unlikely to be at the origin of common 
forms of FMD [71]. On the other hand, increasing epidemiological evidence supports FMD and SCAD 
to be neglected rather than rare and alternative strategies to genetic testing or exome studies to 
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decipher their genetic causes proved to be informative. The study of 26,000 common genetic 
variants in ~250 FMD patients and followed up in >900 patients and ~2,500 controls supported the 
association with FMD of PHACTR1/EDN1[72], a genetic locus on chromosome 6q24 reported to 
confer risk for Coronary Artery Disease and Acute Myocardial Infarction, but in an opposite 
directional effect of the risk allele compared to FMD[73, 74]. PHACTR1/EDN1 risk allele for FMD is 
also associated with migraine [75] and cervical artery dissection[76], supporting shared genetic 
control between these cardiovascular and neurovascular diseases (figure 2). The putative causal 
genetic variant at the PHACTR1 locus has recently reported to lie in a putative enhancer for EDN1, 
the endothelin-1 gene[77]. However, this locus only contributes to a ~40% increased risk for FMD 
and the mechanism that may link a decrease in endothelin-1 circulating levels with an increased risk 
for FMD is still to be determined. These genetic findings suggest that FMD and likely SCAD, are under 
the control of numerous genetic variants, with weak to moderate individual effects.  We expect that 
genetic studies, including well-powered full exome and genome-wide association studies will shed 
light on the full picture of the genetic makeup of FMD and SCAD patients, and potentially enhance 
our scarce knowledge about the underlying biology of these atypical and women-specific vascular 
diseases.   
Connective tissue diseases (CTD) in FMD and SCAD : similarities and differences 
Several arguments suggest the existence of an overlap between FMD and CTDs:  (i) FMD is associated 
with a wide spectrum of vascular abnormalities, including aneurysms, dissections and arterial 
tortuosity [10, 78], which are also part of the phenotype of inherited CTDs such as vascular Ehlers-
Danlos [79] and Loeys-Dietz syndrome [27]; (ii) both FMD and less often CTD can be associated with 
SCAD [1,8 ]; (iii) FMD is a systemic vascular disease, with two or more vascular beds involved in over 
50% of cases [65] and (iv) cases of  patients with Ehlers-Danlos type IV or Marfan syndrome 
coexisting with FMD-like abnormalities [68], or FMD patients with features suggestive of CTD have 
been occasionally reported [80, 81].  
Screening for systemic features suggestive of CTD in patients with FMD (mostly females with 
multifocal FMD) was performed in two cohorts, both from the United States. In 47 FMD patients 
explored at the National Institute on Ageing (NIA, Baltimore) 4 or more features suggestive of mild 
CTD were documented in 95.7% of patients, including hyperlaxity (Beighton score ≥ 5 in 57.4% of 
patients), early onset degenerative spine disease (95.7%), pectus deformity (40.4%) and various 
craniofacial abnormalities [17, 82]. In contrast, in a cohort of 139 patients followed at the Cleveland 
Clinic [80], only 18.7%  of patients harboured ≥ 4 features suggestive of CTD, hyperlaxity (Beighton 
score ≥ 5)  was rare (2.9%), pectus deformities were present in only 7.2% of patients, and other 
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classical CTD features such as hypertelorism or cleft palate were not or seldom observed. Still, 
compared to historical control populations, several characteristics were more often encountered. 
Besides pectus deformities, the latter include palatal abnormalities (56.1%), dental crowding (29.7%), 
moderately severe myopia (29.1%), and early onset arthritis (15.6%). Furthermore, in the same 
cohort [80], several CTD features such as high palate, pneumothorax and atrophic scarring tended to 
be more frequent in patients harbouring at least one arterial dissection or two aneurysms (“high risk 
vascular group”). Discrepancies between both studies [17, 80] may reflect differences in patient 
characteristics and disease severity: in the NIA cohort [16], 21.3% of patients underwent open 
surgery and 48.9% had a cerebrovascular event, while patients from the Cleveland cohort [68] 
appeared more representative of patients included in the US registry. Interestingly, compared to age 
and gender-matched controls, patients with FMD included in the NIA study (n=38) had evidence of 
increased inflammatory markers, including TGF-beta 1 and 2 [17]. In particular, plasma levels of TGF-
beta1 were similar to those observed in patients with Marfan syndrome [83], while, in multivariable 
regression,  plasma TGF-beta2 levels were predictive of the number of arterial beds affected by FMD 
(string-of-beads, aneurysms, stenosis or tortuosity). As mentioned above, TGF-beta 1 and TGF-beta 2 
secretion in dermal fibroblast cell lines of patients with FMD (n=16) was higher than in age and 
gender-matched controls. Finally, in a series of 35 patients with FMD, two variants in the 
transforming growth factor beta receptor 1 (TGFβR1) gene were identified in two unrelated patients, 
both with medial fibroplasia and a history of multivessel dissection [68]. Both variants induced an 
amino acid substitution in a highly conserved region of TGFβR1, however their role is unknown. 
These findings are of interest, since both Loeys-Dietz syndrome, due to mutations in genes encoding 
TGF-beta receptors 1 and 2, and the very rare Aneurysms Osteoarthritis Syndrome, due to mutations 
in SMAD3, are associated with aneurysms, arterial tortuosity and for the latter early-onset 
osteoarthritis [27, 28] . Still, as mentioned above, the yield of genetic screening oriented by clinical 
indications (including genes such as TGFβR2, COL3A1, FBN1, ACTA2, or SMAD3) was low [17, 68]. 
As a whole, while arterial aneurysms, dissections and arterial tortuosity may occur both in FMD and 
several inherited CTDs, the typical string-of-beads (figure 1) is almost pathognomonic of multifocal 
FMD [10, 78]. Even in FMD patients with extra-vascular features suggestive of CTD, mutations in 
genes at the origin of inherited CTDs are seldom identified. Still, CTD clinical features are probably 
more frequent in patients with FMD than in healthy controls, but their exact prevalence remains to 
be determined in larger and more diverse cohorts, compared with matched controls from the same 
populations. Whatever their prevalence, CTD-like extravascular abnormalities identified in patients 
with FMD appear to be milder than those observed in CTDs. Thus, major complications suggestive of 
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CTD such as hollow organ rupture associated with a history of arterial aneurysms or dissection should 
prompt genetic screening for CTDs, even in presence of vascular images compatible with FMD [68].  
SCAD has also been associated with CTD, especially Marfan syndrome and  vascular Ehlers– Danlos 
syndrome [84, 85]. In clinical practice genetic screening is not routinely performed in SCAD patients 
and often randomly done in those who have signs of hypermobility or Marfan-like physical 
characteristics. Data from a single center patient series showed that 3 out of 59 patients had a clear 
CTD mutation (FBN1 and COL3A1), 20.3% had genetic variants of unknown significance, but a distinct 
vascular phenotype was not identified [86]. Further genetic studies are warranted in SCAD patients 
to unravel potential CTD abnormalities. 
 
Conclusion   
The vast majority of patients diagnosed with SCAD and FMD are women below 60 years of age. 
Although the mutual relationship of both entities is complex and only partly understood, there seems 
to be some overlap in genetic background and interaction with endogenous sex-steroids. A variety of 
external factors and co-morbidities interfere with their occurrence. A diversity of phenotypes of FMD 
are expressed in individuals, leading to a heterogeneous group of patients. Identification of 
susceptibility genes and associated biomarkers, as well as careful study of hormonal profile, in 
correlation with various clinical presentations will help unraveling the pathophysiology and 
improving the classification of this intriguing group of diseases. The final aim would be to 
individualize management and follow-up according to each patient’s specificities, with particular 
attention to sex and gender-related issues such as pregnancy, breastfeeding or exogenous hormonal 
intake.  
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